WST
West Pharmaceutical Services, Inc.266.44
-5.42-1.99%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Conservative GLP-1, strong non-GLP demand
Q&A underscored conservatism in West's 2026 GLP-1 guide, with 10% growth at midpoint assuming over 30% oral penetration by 2030—far above expectations—while non-GLP-1 HVP demand outstrips supply across plants. No customer shifts despite oral launches; biologics and Annex 1 drive acceleration from flat FY2025 to high single/low double digits. Capacity ramps continue in Europe, Dublin drug handling eyes $20M ramping H2. Management opened door to accretive M&A and buybacks atop organic focus. Demand exceeds capacity now. Regulatory scrutiny boosts Annex 1 talks. Upbeat tone prevails; watch non-GLP durability.
Key Stats
Market Cap
19.17BP/E (TTM)
39.53Basic EPS (TTM)
6.74Dividend Yield
0%Recent Filings
8-K
CEO Green to retire H2 2026
West Pharmaceutical Services announced CEO Eric M. Green's planned retirement from his roles as President, CEO, and Board Chair once a successor is hired, with transition eyed for H2 2026. The Board tapped a top recruiter for the search. Company reaffirms 2026 guidance amid the shift. Leadership change tests succession depth.
10-K
FY2025 results
West Pharmaceutical Services posted FY2025 net sales of $3.1B, up 6.3% y/y including $56M currency tailwind, with Proprietary Products driving 6.8% growth to $2.5B on Westar, NovaChoice, and Envision demand despite $47M customer incentives not repeating from 2024. Gross margins expanded 140bps to 35.9% via high-value components and absorption, lifting operating profit 2.6% to $585M; diluted EPS hit $6.79. Q4 momentum shone in sequential trends, though quarterly breakdowns undisclosed. Cash swelled to $791M on $755M operating cash flow, funding $286M capex and $134M buybacks while lifting dividends to $0.22/share. SmartDose sale to AbbVie pending. Supply chain disruptions threaten quarterly momentum.
8-K
Q4 sales beat, HVP soars
West Pharmaceutical Services reported Q4 2025 net sales of $805M, up 7.5% with 3.3% organic growth, powered by 20.3% surge in HVP Components to $389.8M—48% of total. Adjusted-diluted EPS climbed 12.1% to $2.04, while full-year sales hit $3.074B. HVP Delivery Devices dropped 16.9% sans prior $25M fee. Guides 2026 sales to $3.215B-$3.275B, adjusted EPS $7.85-$8.20. SmartDose sale to AbbVie closes mid-year.
10-Q
Q3 FY2025 results
West Pharmaceutical Services posted solid Q3 results ended September 30, 2025, with net sales up 7.7% y/y to $804.6M (Proprietary Products +7.7% y/y to $647.5M) while gross margin expanded 1.2 points to 36.6% on higher plant absorption and pricing, driving operating profit up 3.9% y/y to $167.6M and diluted EPS to $1.92 (up 3.8% y/y, reconciles to 72.6M shares). YTD sales rose 5.8% y/y to $2,269.1M, operating profit +4.4% y/y to $428.3M, and EPS +1.2% y/y to $4.97 (reconciles to 72.7M shares). Cash swelled to $628.5M on $503.7M operating cash flow (up y/y), yielding $293.9M free cash flow (derived), against steady $202.7M debt and $497.7M revolver availability. Restructuring hit $17.5M YTD, yet margins held. Share repurchases totaled $134.0M YTD. Competition from lower-cost producers looms.
8-K
Q3 sales beat, guidance up
West Pharmaceutical Services reported Q3 2025 net sales of $804.6 million, up 7.7% and 5.0% organically, fueled by 16.3% HVP Components growth to $390 million amid GLP-1 and Annex 1 demand. Diluted EPS hit $1.92; adjusted $1.96. HVP Delivery Devices dropped 15.7% sans prior-year $19 million fee. Full-year guidance rose to $3.06-$3.07 billion sales, $7.06-$7.11 adjusted EPS. Momentum builds.
IPO
Website
Employees
Sector
Industry
ATR
AptarGroup, Inc.
122.83+0.50
AVTR
Avantor, Inc.
11.20-0.08
BAX
Baxter International Inc.
19.05-0.48
BDX
Becton, Dickinson and Company
196.39-3.70
CAH
Cardinal Health, Inc.
197.89-2.07
MCK
McKesson Corporation
809.96-13.05
MMSI
Merit Medical Systems, Inc.
86.85+0.44
SHTPY
-
7.65+0.00
STSS
Sharps Technology Inc.
2.22+0.00
STVN
Stevanato Group S.p.A.
20.89-0.41